Molecular Drivers of Aortic Remodeling After Left Ventricular Assist Device
I could only partially view this paper as an image so couldn't copy paste. Full viewing required a subscription/paying etc
So I asked ai to give me a 300 word analysis focusing on possible Leron benefits.
https://journals.lww.com/asaiojournal/citatio...t.893.aspx
Analysis: Leronlimab's Potential in LVAD-Induced Aortic Remodeling
.
"Left ventricular assist devices create significant molecular and structural chal the aortic valve and wall. Continuous-flow LVADs subject the aortic root to constant high-pressure loads while reducing wall shear stress, triggering pathological remodeling including collagen proliferation, valve deterioration, and commissural fusion
MDPI
.
The inflammatory cascade appears central to LVAD-associated aortic pathology. Studies reveal significant upregulation of interferon gamma, IL-1 beta, and TNF-α in aortic valves of LVAD patients
MDPI
. Additionally, matrix metalloproteinase-9, α-SMA, and osteopontin expression increases substantially
MDPI
. The fibrotic response intensifies over time, with adventitial layer thickness and fibrillar collagen content increasing proportionally to LVAD support duration
MDPI
.
Leronlimab, as a CCR5 antagonist, presents compelling therapeutic potential for this inflammatory-fibrotic pathology. CCR5 signaling pathways are involved in monocyte recruitment, macrophage activation, and fibroblast stimulation—precisely the mechanisms driving LVAD-associated aortic remodeling. By blocking CCR5, leronlimab could attenuate the inflammatory cytokine cascade, potentially reducing TNF-α and IL-1β-mediated tissue damage.
The drug's anti-fibrotic properties may prove particularly valuable given the progressive collagen deposition observed in LVAD-supported aortas. CCR5 inhibition has demonstrated capacity to reduce transforming growth factor-β signaling and matrix metalloproteinase activity in other fibrotic conditions, suggesting it could mitigate structural deterioration.
Early prophylactic leronlimab administration at LVAD implantation could prevent rather than merely treat remodeling. This preventive strategy might preserve aortic valve function, reduce regurgitation incidence, and improve long-term outcomes for both bridge-to-transplant and destination therapy patients.
Clinical investigation would need to establish optimal dosing, assess safety interactions with mandatory anticoagulation regimens, and determine whether leronlimab can meaningfully alter the natural history of LVAD-associated aortic pathology.
I could only partially view this paper as an image so couldn't copy paste. Full viewing required a subscription/paying etc
So I asked ai to give me a 300 word analysis focusing on possible Leron benefits.
https://journals.lww.com/asaiojournal/citatio...t.893.aspx
Analysis: Leronlimab's Potential in LVAD-Induced Aortic Remodeling
.
"Left ventricular assist devices create significant molecular and structural chal the aortic valve and wall. Continuous-flow LVADs subject the aortic root to constant high-pressure loads while reducing wall shear stress, triggering pathological remodeling including collagen proliferation, valve deterioration, and commissural fusion
MDPI
.
The inflammatory cascade appears central to LVAD-associated aortic pathology. Studies reveal significant upregulation of interferon gamma, IL-1 beta, and TNF-α in aortic valves of LVAD patients
MDPI
. Additionally, matrix metalloproteinase-9, α-SMA, and osteopontin expression increases substantially
MDPI
. The fibrotic response intensifies over time, with adventitial layer thickness and fibrillar collagen content increasing proportionally to LVAD support duration
MDPI
.
Leronlimab, as a CCR5 antagonist, presents compelling therapeutic potential for this inflammatory-fibrotic pathology. CCR5 signaling pathways are involved in monocyte recruitment, macrophage activation, and fibroblast stimulation—precisely the mechanisms driving LVAD-associated aortic remodeling. By blocking CCR5, leronlimab could attenuate the inflammatory cytokine cascade, potentially reducing TNF-α and IL-1β-mediated tissue damage.
The drug's anti-fibrotic properties may prove particularly valuable given the progressive collagen deposition observed in LVAD-supported aortas. CCR5 inhibition has demonstrated capacity to reduce transforming growth factor-β signaling and matrix metalloproteinase activity in other fibrotic conditions, suggesting it could mitigate structural deterioration.
Early prophylactic leronlimab administration at LVAD implantation could prevent rather than merely treat remodeling. This preventive strategy might preserve aortic valve function, reduce regurgitation incidence, and improve long-term outcomes for both bridge-to-transplant and destination therapy patients.
Clinical investigation would need to establish optimal dosing, assess safety interactions with mandatory anticoagulation regimens, and determine whether leronlimab can meaningfully alter the natural history of LVAD-associated aortic pathology.
9
